Every 10-Q that Stryker Corporation (SYK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SYK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYK filings page.
Stryker Corporation reported strong Q2 2026 results, with net sales of $ 6,589 versus $ 6,022 in 2025 and net earnings of $ 1,276, or $ 3.30 per diluted share. Gross profit margin improved to 68.3% and operating margin to 25.2%, helped by lower import tariffs and reduced inventory step-up amortization.
For the first six months of 2026, net sales were $ 12,609 and net earnings were $ 2,021, or $ 5.23 per diluted share. Adjusted net earnings per diluted share were $ 3.69 in Q2 and $ 6.29 year to date. Operating cash flow increased to $ 1,842, while total debt decreased to $ 14,942 after repaying $ 1,000 of senior notes. Stryker also completed the AVS acquisition for $ 435 in cash plus up to $ 400 in contingent milestone payments, adding a next-generation intravascular lithotripsy platform to its Peripheral Vascular business.
Stryker Corporation reported solid first-quarter 2026 results with net sales of $6.02 billion, up from $5.87 billion a year earlier, driven mainly by MedSurg and Neurotechnology growth. Net earnings rose to $745 million, and diluted EPS increased to $1.93.
Adjusted diluted EPS was $2.60, down 8.5% from 2025 as adjusted operating margin contracted to 21.1%. A March 11, 2026 cybersecurity incident caused idle production time, pressuring gross margin to 63.3% and segment margins, though manufacturing operations and commercial systems have been restored. Cash from operations improved to $581 million, while the company repaid $1.0 billion of maturing notes and ended the quarter with $2.97 billion in cash and marketable securities.
Stryker (SYK) filed its Q3 2025 10‑Q reporting double‑digit top‑line growth. Net sales rose to $6,057 million from $5,494 million, and diluted EPS was $2.22 versus $2.16. For the nine months, revenue reached $17,945 million with diluted EPS of $6.20.
Growth was broad-based: MedSurg and Neurotechnology sales increased 14.4% to $3,803 million, while Orthopaedics rose 3.9% to $2,254 million. Vascular and Neuro Cranial stood out, reflecting the February acquisition of Inari Medical, which added minimally invasive venous thromboembolism products. Operating income was $1,135 million, and net earnings were $859 million.
Cash flow from operations improved to $2,901 million for the nine months, while investing cash flow of $(4,561) million reflected $4,810 million for the Inari acquisition. The company issued $3,000 million of senior notes and repaid $650 million, ending with total debt of $16,595 million and cash of $3,256 million. Stryker completed the sale of its Spinal Implants business. Shares outstanding were 382,423,648 as of September 30, 2025.